Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
RESEARCH TOOLSreports
Holding IKT?
Track your performance easily
IKT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.12 - $4.20
Previous Close$3.21
Volume102.08K
Average Volume (3M)672.87K
Market Cap
$212.33M
Enterprise Value$209.23M
Total Cash (Recent Filing)$3.24M
Total Debt (Recent Filing)$145.21K
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Mar 27, 2025EPS Estimate
-$0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.72
Shares Outstanding67,192,570
10 Day Avg. Volume142,676
30 Day Avg. Volume672,874
Standard Deviation0.32
R-Squared0.03
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)-310.00
Price to Sales (P/S)1100.56
Price to Cash Flow (P/CF)-11.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit803.18
Enterprise Value/Ebitda-10.25
Forecast
1Y Price Target
$7.00Price Target Upside125.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Inhibikase Therapeutics News
PremiumCompany Announcements
Inhibikase Adjusts and Terminates Stock Offering Agreement
PremiumCompany Announcements
Inhibikase Therapeutics Reports Q3 2024 Financial Results
PremiumCompany Announcements
Inhibikase Therapeutics Secures Funding and Strengthens LeadershipBulls Say, Bears Say
Bulls Say
Financial PerformanceThe company's recent $100M+ PIPE addresses balance sheet concerns and supports reaching key Phase IIB efficacy data milestones.
Product DevelopmentInhibikase is finalizing a new dosage form for IkT-001Pro to align with FDA feedback, aiming to differentiate its formulation from generic imatinib mesylate.
Regulatory ApprovalFDA has agreed to an accelerated 505(b)(2) pathway, allowing IKT to leverage imatinib's existing approval for a potentially faster development process.
Bears Say
Clinical RiskThere is still execution and clinical risk over the medium to longer term for PAH treatment.
EarningsInhibikase reported 3Q24 EPS of ($0.65).
Equity FinancingWhile the equity financing was significantly dilutive, the elimination of the near-term financing overhang is viewed positively.
---
Ownership Overview
10.87% Insiders
0.09% Mutual Funds
0.93% Other Institutional Investors
88.08% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IKT FAQ
What was Inhibikase Therapeutics’s price range in the past 12 months?
Inhibikase Therapeutics lowest stock price was $1.12 and its highest was $4.20 in the past 12 months.
What is Inhibikase Therapeutics’s market cap?
Currently, no data Available
When is Inhibikase Therapeutics’s upcoming earnings report date?
Inhibikase Therapeutics’s upcoming earnings report date is Mar 27, 2025 which is in 75 days.
How were Inhibikase Therapeutics’s earnings last quarter?
Inhibikase Therapeutics released its earnings results on Nov 14, 2024. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.48 by -$0.17.
Is Inhibikase Therapeutics overvalued?
According to Wall Street analysts Inhibikase Therapeutics’s price is currently Undervalued.
Does Inhibikase Therapeutics pay dividends?
Inhibikase Therapeutics does not currently pay dividends.
What is Inhibikase Therapeutics’s EPS estimate?
Inhibikase Therapeutics’s EPS estimate is -$0.09.
How many shares outstanding does Inhibikase Therapeutics have?
Inhibikase Therapeutics has 67,192,570 shares outstanding.
What happened to Inhibikase Therapeutics’s price movement after its last earnings report?
Inhibikase Therapeutics reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.48. Following the earnings report the stock price went down -2.479%.
Which hedge fund is a major shareholder of Inhibikase Therapeutics?
Currently, no hedge funds are holding shares in IKT
---
Inhibikase Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (125.81% Upside)
$7.00 (125.81% Upside)
Insider Transactions
Bought Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.5%
Last 30 Days ▲ 10.1%
Last 30 Days ▲ 10.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
139.55%
12-Months-Change
Fundamentals
Return on Equity
-270.10%
Trailing 12-Months
Asset Growth
-75.52%
Trailing 12-Months
Company Description
Inhibikase Therapeutics
Inhibikase Therapeutics Inc is a clinical stage pharmaceutical company developing therapeutics for Parkinson's Diseases and related disorders inside and outside the brain. Its pipeline product, IkT-148009, targets underlying disease mechanisms to reverse the course of Parkinson's disease and the GI complications of Parkinson's disease.
---
IKT Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments, such as the completion of trial enrollments and financial strengthening, alongside challenges like observed adverse events and increased expenses. The potential for significant advancements, particularly in PAH and Parkinson's disease treatments, is promising, though tempered by some operational hurdles.Read More>---
IKT Stock 12 Month Forecast
Average Price Target
$7.00
▲(125.81% Upside)
Technical Analysis
Abeona Therapeutics
―
Adaptimmune Therapeutics
―
Actinium Pharmaceuticals
―
Cellectar Biosciences
―
Best Analysts Covering IKT
1 Year
1 Year Success Rate
6/6 ratings generated profit
1 Year Average Return
+58.83%
reiterated a buy rating 2 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +58.83% per trade.
---